Motosol (Ambroxol Hydrochloride)

Ambroxol Hydrochloride, the active ingredient in Motosol, is a mucolytic presented as an injection for intravenous use. It reduces mucus viscosity, stimulates surfactant production and enhances mucociliary clearance, thereby facilitating expectoration and improving airway patency in patients with acute bronchitis, chronic obstructive pulmonary disease (COPD) exacerbations, respiratory tract infections with excessive mucus, and those who are intubated.

GNH USA supplies Motosol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, clinics and procurement teams worldwide, ensuring quality and regulatory compliance across markets.

Motosol (Ambroxol Hydrochloride) acts on respiratory mucus to improve clearance in several clinical settings.

- Acute bronchitis: reduces mucus thickness and aids expectoration, helping relieve cough and airway obstruction. - COPD exacerbations: facilitates sputum clearance, supporting recovery and reducing ventilation difficulty. - Respiratory tract infections with excessive mucus: lowers viscosity to improve patient comfort and oxygenation. - Intubated patients: promotes airway mucus clearance, decreasing risk of ventilator‑associated complications.

Adverse reactions to Ambroxol Hydrochloride injection are generally infrequent but may occur.

Common Side Effects: - Injection site pain: mild discomfort at the infusion site. - Nausea: transient feeling of queasiness. - Headache: mild to moderate headache. - Dizziness: occasional light‑headed sensation. - Fever: low‑grade temperature rise. - Vomiting: occasional episodes of emesis.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Severe skin rash: extensive urticaria or Stevens‑Johnson‑like eruption. - Cardiac arrhythmia: rare occurrence of irregular heartbeat.

When using Motosol, several precautions should be observed to ensure patient safety.

- Indication verification: confirm the patient has a condition requiring mucolytic therapy. - Renal function: assess kidney function as the drug is primarily excreted renally. - Hepatic impairment: use with caution in patients with liver disease. - Concomitant respiratory therapy: monitor for additive effects with other mucolytics or bronchodilators. - Allergy assessment: check for known hypersensitivity to Ambroxol or excipients. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ambroxol Hydrochloride may interact with certain medicines; awareness of these interactions helps manage therapy.

Major Interactions (Avoid): - Anticholinergic agents: may reduce mucociliary clearance, diminishing therapeutic benefit. - Beta‑agonists: concurrent high doses can increase risk of cardiovascular side effects.

Moderate Interactions (Monitor Closely): - Other mucolytics (e.g., N‑acetylcysteine): additive mucolytic effect may cause excessive sputum production. - Bronchodilators: monitor for enhanced bronchial responsiveness. - CYP450 substrates: Ambroxol may modestly inhibit CYP enzymes, requiring dose adjustment of sensitive drugs.